SCHEMBL2365529

SCHEMBL2365529

CN(C)c1cccc(OCCC2CCN(C(=O)OCc3cncs3)CC2)c1

nearest known ligand 0.41

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.40
TEAD1 P28347 1/20 0.39
TEAD3 Q99594 1/20 0.39
GRIN2B Q13224 11/20 0.39
EPHX2 P34913 1/20 0.37
GPR119 Q8TDV5 2/20 0.37
FAAH O00519 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2229063 0.88 GPR119 (0.41) CYP3A4TEAD1TEAD3GRIN2BGPR119
SCHEMBL2226276 0.86 TEAD1 (0.53) CYP3A4TEAD1TEAD3GRIN2BFAAH
SCHEMBL2228392 0.86 TEAD1 (0.45) CYP3A4TEAD1TEAD3GRIN2BFAAH
SCHEMBL2229682 0.86 TEAD1 (0.45) CYP3A4TEAD1TEAD3GRIN2BFAAH
SCHEMBL2227859 0.85 RAB9A (0.49) TEAD1TEAD3GRIN2B
SCHEMBL2227968 0.84 MGLL (0.47) TEAD1TEAD3FAAH
SCHEMBL2227973 0.84 TEAD1 (0.41) CYP3A4TEAD1TEAD3GRIN2BGPR119
SCHEMBL2228627 0.84 MEN1 (0.42) CYP3A4TEAD1TEAD3GRIN2BGPR119
SCHEMBL2365563 0.83 MMP2 (0.40) TEAD1TEAD3GRIN2BGPR119
SCHEMBL2231121 0.83 GRIN2B (0.43) CYP3A4TEAD1TEAD3GRIN2BGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US claimed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP claimed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US claimed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO claimed
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US disclosed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP disclosed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US disclosed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION PRMT9, PRMT8, CBR1 CYP3A4 724/4885TEAD1 4192/4885TEAD3 3201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.